EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients

Michael Li, Danny Wong, Jordan S Sack, Alexander S Vogel, F Stephen Hodi, Lawrence Fong, Jennifer C Lai, Stephen D Zucker, Shilpa Grover

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2024.02.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Michael Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California. Electronic address: michael.li@ucsf.…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Hospitalization, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIDDK, American College of Gastroenterology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Guidelines recommend hospitalization for severe immune checkpoint inhibitor (ICI) hepatitis. We compared patient outcomes in the inpatient versus outpatient settings. METHODS: We conducted a multicenter, retrospective cohort study of 294 ICI-treated patients who developed grade 3-4 ICI hepatitis. The primary outcome was time to alanine aminotransferase (ALT) normalization (≤40); secondary outcomes included time to ALT ≤100 U/L and time to death. To account for confounding by indication, inverse probability of treatment weighting was applied to perform Cox regression. A sensitivity analysis was performed excluding patients with grade 4 hepatitis. RESULTS: One hundred and sixty-six patients (56.5%) were hospitalized for a median of 6 (interquartile range, 3-11) days. On inverse probability of treatment weighting Cox regression, hospitalization was not associated with time to ALT normalization (hazard ratio [HR], 1.11; 95% confidence interval [CI], 0.86-1.43; P = .436) or time to ALT ≤100 U/L (HR, 1.11; 95% CI, 0.86-1.43; P = .420). In the sensitivity analysis limited to patients with grade 3 hepatitis, hospitalization was also not associated with time to ALT normalization (HR, 1.11; 95% CI, 0.83-1.50; P = .474) or time to ALT ≤100 U/L (HR, 1.19; 95% CI, 0.90-1.58; P = .225). In a subgroup analysis of 152 patients with melanoma, hospitalization was not associated with reduced risk of all-cause death (HR, 0.93; 95% CI, 0.53-1.64; P = .798). Notably, despite their Common Terminology Criteria for Adverse Events classification of high-grade hepatitis, 94% of patients had "mild" liver injury based on International Drug-Induced Liver Injury Criteria. CONCLUSIONS: Hospitalization of patients with high-grade ICI hepatitis was not associated with faster hepatitis resolution and did not affect mortality. Routine hospitalization may not be necessary in all patients with high-grade ICI hepatitis and Common Terminology Criteria for Adverse Events criteria may overestimate severity of liver injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsHospitalizationChemical and Drug Induced Liver InjuryHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAlanine Transaminase

Stichwörter der Autor:innen

Drug-Induced Liver InjuryImmune-Related Adverse EventImmunotherapy

Substanzen

Immune Checkpoint InhibitorsAlanine Transaminase

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California. Electronic address: michael.li@ucsf.edu.
  • Division of Gastroenterology, Hepatology, and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California.
  • Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California.

Förderung

  • NIDDK NIH HHS
  • NIDDK
  • American College of Gastroenterology

Zitieren

APA

Li, M., Wong, D., Sack, J. S., Vogel, A. S., Hodi, F. S., Fong, L., Lai, J. C., Zucker, S. D., & Grover, S. (2024). Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.02.006

Vancouver

Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, et al. Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2024.02.006

BibTeX
@article{Li2024,
  author = {Li, Michael and Wong, Danny and Sack, Jordan S and Vogel, Alexander S and Hodi, F Stephen and Fong, Lawrence and Lai, Jennifer C and Zucker, Stephen D and Grover, Shilpa},
  title = {Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2024.02.006}
}
Kostenlos starten →